AlphAIAlphAI — Financial news for AI agents
medicaldaily.comSEP 93 min read$NVS

Late Stage Trial Miss Leaves Adults with Myotonic Dystrophy Still Waiting for a First Approved Treatment

Novartis' Phase 3 trial of del-desiran for myotonic dystrophy type 1 failed to meet its primary endpoint, video hand opening time. The company will review data and consult regulators. Del-desiran is not yet approved, and no treatment timeline is set. Novartis shares fell, along with those of Dyne and Sarepta, which are developing similar therapies.

Original reporting
medicaldaily.com
Published Sep 9, 2026, 7:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Late Stage Trial Miss Leaves Adults with Myotonic Dystrophy Still Waiting for a First Approved Treatment — source image
Source · medicaldaily.com
Decision brief

The 30-second read

$NVSBearishMed
01

Why it matters

The immediate market reaction was a sharp sell‑off in Novartis, Dyne and Sarepta stocks, reflecting concerns over the platform's viability.

02

Market read

First report of a pivotal trial miss for a high‑profile rare‑disease asset, driving immediate negative price action across related biotech stocks.

03

What to watch

Potential regulatory discussions and the possibility of a different primary endpoint could mitigate the impact.

Relevance 8/10Novelty 8/10Timing: Sept 8 announcement, same‑day impact

Background

Novartis' del-desiran was a late‑stage candidate for myotonic dystrophy type 1, acquired via Avidity Biosciences. The trial failure affects peers with similar siRNA approaches.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis announced its Phase 3 HARBOR trial of del-desiran failed to meet the primary endpoint.

Expected impact

downward pressure, potential 5-10% decline in near term

Evidence & confidence

First disclosure of a pivotal trial failure for a late‑stage asset; market typically reacts sharply to such news.

$SRPTBearishMedium confidence
Context

Sarepta Therapeutics shares fell 15.5% in U.S. pre‑market trading following the trial failure news.

Expected impact

moderate decline, 5‑8% drop

Evidence & confidence

Similar therapeutic approach; market likely to penalize related candidates.

Market effects

Sector

The setback may dampen sentiment across the broader biotech/siRNA sector.

Regional

European and U.S. biotech stocks could see heightened volatility.

Global

Global investors tracking rare‑disease pipelines may adjust exposure.

Counterpoint

What could challenge this read

If secondary endpoints show meaningful signals, the market could rebound on deeper data release.

Key entities

  • Company
    Novartis

    Swiss pharma giant, ticker NVS

  • Company
    Dyne Therapeutics

    U.S. biotech, ticker DYNE

  • Company
    Sarepta Therapeutics

    U.S. biotech, ticker SRPT

Read at source← All news

Related articles

OCT 7
$NVSHigh

FDA Approves First Symptomatic Dermographism Treatment

The FDA approved Novartis' remibrutinib (Rhapsido) on October 7, 2026, as the first treatment for adults with symptomatic dermographism (SD) not controlled by H1 antihistamines. The drug, an oral BTK inhibitor, also treats chronic spontaneous urticaria (CSU). The approval was based on phase 3 trial data showing higher complete response rates from hives compared to placebo. Novartis plans further submissions for other immune-mediated conditions.

ajmc.com2 min
OCT 7
$NVSHigh

Why Is Novartis Stock Trading Higher Today? - Novartis (NYSE:NVS)

Novartis (NYSE: NVS) received FDA approval for Rhapsido to treat symptomatic dermographism (SD). The drug is the first approved for SD and also treats chronic spontaneous urticaria (CSU). Clinical trials showed 29.3% of patients achieved complete hive clearance. NVS shares rose 1.91% to $143.47. The company is also studying remibrutinib for other conditions.

benzinga.com2 min
OCT 7
$NVSMed

Novartis Presents New Multiple Sclerosis Portfolio Data From Phase III REMODEL-1/-2 Trials And Kesimpta Evidence At MSToronto2026

Novartis will present 46 abstracts at MSToronto2026, including Phase III REMODEL-1/-2 results for remibrutinib and new Kesimpta data in pediatric MS. Additional Kesimpta research covers pregnancy outcomes and comparisons with first-line treatments. Novartis will host an investor call post-presentation to discuss remibrutinib's potential in MS.

marketscreener.com2 min
OCT 7
$NVSHigh

Rhapsido Approved as First Treatment for Symptomatic Dermographism

FDA expanded approval of Novartis' Rhapsido (remibrutinib) to treat symptomatic dermographism, a skin condition causing chronic hives. The approval follows positive phase 3 trial results showing significant symptom reduction. Rhapsido was previously approved for chronic spontaneous urticaria. According to Novartis, this marks an important milestone for treating chronic hives.

empr.com2 min
OCT 7
$NVSHigh

US FDA expands use of Novartis drug for chronic skin condition

The US FDA expanded approval of Novartis' drug remibrutinib (Rhapsido) to treat adults with symptomatic dermographism, a chronic skin condition. The drug is now approved for two forms of chronic hives. In trials, 29.3% of patients saw complete resolution of hives after 12 weeks, versus 14% on placebo. Novartis reports improvements as early as two weeks. The drug's safety profile was consistent with earlier studies.

finance.yahoo.com2 min